---
document_datetime: 2025-12-02 04:56:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/inaqovi.html
document_name: inaqovi.html
version: success
processing_time: 0.1085706
conversion_datetime: 2025-12-28 00:27:36.89044
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Inaqovi

[RSS](/en/individual-human-medicine.xml/67710)

##### Authorised

This medicine is authorised for use in the European Union

cedazuridine / decitabine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Inaqovi](#news-on)
- [More information on Inaqovi](#more-information-on-inaqovi-63788)
- [More information on Inaqovi](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Inaqovi is a cancer medicine used in adults to treat newly diagnosed acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells. It is used in patients who are not eligible for standard induction chemotherapy (initial treatment with cancer medicines).

Inaqovi contains two active substances, decitabine and cedazuridine.

Expand section

Collapse section

## How is Inaqovi used?

The medicine can only be obtained with a prescription. Treatment with Inaqovi should be started and supervised by a doctor who has experience in the use of cancer treatments.

Inaqovi is available as tablets to be taken by mouth over cycles that last for 28 days. It is given once a day for the first 5 days of each cycle. The medicine is given for a minimum of 4 cycles or until the disease gets worse or side effects become unacceptable.

For more information about using Inaqovi, see the package leaflet or contact your doctor or pharmacist.

## How does Inaqovi work?

The two active substances in Inaqovi, decitabine and cedazuridine, work in different ways. Decitabine is analogous (comparable) to cytidine, a fundamental component of the DNA (genetic material) in cells. In the body, it is incorporated into the DNA where it blocks the activity of enzymes (proteins) called DNA methyltransferases (DNMTs). These enzymes promote the development and progression of cancer. By blocking DNMTs, decitabine impacts the increase of tumour cells and lead to their death.

Cedazuridine blocks the action of an enzyme which breaks down decitabine in the gut and liver. This prevents the premature breakdown of decitabine when it is given by mouth.

## What benefits of Inaqovi have been shown in studies?

The benefits of Inaqovi were evaluated in an ongoing study involving 89 adults with newly diagnosed AML. Within the study patients were divided into two groups. For the first cycle of treatment, one group was given Inaqovi once daily for five days while the second group was given decitabine by infusion (drip) into a vein once daily for five days. For the second cycle, the treatments were reversed (i.e. the group given Inaqovi for the first cycle was given decitabine by infusion and vice versa). For the third and subsequent cycles, all patients were given Inaqovi.

Results showed that Inaqovi achieved the same levels of decitabine in the body as those observed when decitabine was given by infusion. In addition, results showed that 21% (19 out of 87) of patients achieved a complete response (no sign of cancer). On average, patients achieved a complete response 3 months after starting treatment. Complete responses to Inaqovi lasted for an average of approximately six months.

## What are the risks associated with Inaqovi?

For the full list of side effects and restrictions with Inaqovi, see the package leaflet.

The most common side effects with Inaqovi (which may affect more than 1 in 10 people) include thrombocytopenia (low levels of blood platelets, components which help the blood to clot).

The most common serious side effects are pneumonia (infection of the lungs) and febrile neutropenia (low levels of white blood cells with fever).

Inaqovi must not be used in women who are breast-feeding.

## Why is Inaqovi authorised in the EU?

Inaqovi was shown to achieve the same levels of decitabine in the body as formulations of decitabine given by infusion; it is therefore expected to have the same effect in the treatment of adults with AML. Patients not suitable for induction therapy are often treated with medicines given by injection. As Inaqovi is a tablet given by mouth, it reduces the burden associated with receiving infusions for both patients and their caregivers. The side effects of Inaqovi are similar to those of formulations of decitabine given by infusion. Although the safety data for Inaqovi are limited, no new side effects associated with either cedazuridine or by giving decitabine by mouth were identified.

The European Medicines Agency decided that Inaqovi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Inaqovi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Inaqovi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Inaqovi are continuously monitored. Suspected side effects reported with Inaqovi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Inaqovi

Inaqovi received a marketing authorisation valid throughout the EU on 15 September 2023.

Inaqovi : EPAR - Medicine overview

Reference Number: EMA/347549/2023

English (EN) (121.54 KB - PDF)

**First published:** 30/11/2023

[View](/en/documents/overview/inaqovi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-387)

български (BG) (147.32 KB - PDF)

**First published:**

30/11/2023

[View](/bg/documents/overview/inaqovi-epar-medicine-overview_bg.pdf)

español (ES) (120.6 KB - PDF)

**First published:**

30/11/2023

[View](/es/documents/overview/inaqovi-epar-medicine-overview_es.pdf)

čeština (CS) (143.4 KB - PDF)

**First published:**

30/11/2023

[View](/cs/documents/overview/inaqovi-epar-medicine-overview_cs.pdf)

dansk (DA) (119.32 KB - PDF)

**First published:**

30/11/2023

[View](/da/documents/overview/inaqovi-epar-medicine-overview_da.pdf)

Deutsch (DE) (123.83 KB - PDF)

**First published:**

30/11/2023

[View](/de/documents/overview/inaqovi-epar-medicine-overview_de.pdf)

eesti keel (ET) (118.51 KB - PDF)

**First published:**

30/11/2023

[View](/et/documents/overview/inaqovi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (152.71 KB - PDF)

**First published:**

30/11/2023

[View](/el/documents/overview/inaqovi-epar-medicine-overview_el.pdf)

français (FR) (121.96 KB - PDF)

**First published:**

30/11/2023

[View](/fr/documents/overview/inaqovi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.31 KB - PDF)

**First published:**

30/11/2023

[View](/hr/documents/overview/inaqovi-epar-medicine-overview_hr.pdf)

italiano (IT) (118.44 KB - PDF)

**First published:**

30/11/2023

[View](/it/documents/overview/inaqovi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (156.38 KB - PDF)

**First published:**

30/11/2023

[View](/lv/documents/overview/inaqovi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.94 KB - PDF)

**First published:**

30/11/2023

[View](/lt/documents/overview/inaqovi-epar-medicine-overview_lt.pdf)

magyar (HU) (141.15 KB - PDF)

**First published:**

30/11/2023

[View](/hu/documents/overview/inaqovi-epar-medicine-overview_hu.pdf)

Malti (MT) (143.41 KB - PDF)

**First published:**

30/11/2023

[View](/mt/documents/overview/inaqovi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (119.55 KB - PDF)

**First published:**

30/11/2023

[View](/nl/documents/overview/inaqovi-epar-medicine-overview_nl.pdf)

polski (PL) (144.61 KB - PDF)

**First published:**

30/11/2023

[View](/pl/documents/overview/inaqovi-epar-medicine-overview_pl.pdf)

português (PT) (120.78 KB - PDF)

**First published:**

30/11/2023

[View](/pt/documents/overview/inaqovi-epar-medicine-overview_pt.pdf)

română (RO) (147.36 KB - PDF)

**First published:**

30/11/2023

[View](/ro/documents/overview/inaqovi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (141.03 KB - PDF)

**First published:**

30/11/2023

[View](/sk/documents/overview/inaqovi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (139.13 KB - PDF)

**First published:**

30/11/2023

[View](/sl/documents/overview/inaqovi-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.68 KB - PDF)

**First published:**

30/11/2023

[View](/fi/documents/overview/inaqovi-epar-medicine-overview_fi.pdf)

svenska (SV) (118.01 KB - PDF)

**First published:**

30/11/2023

[View](/sv/documents/overview/inaqovi-epar-medicine-overview_sv.pdf)

Inaqovi : EPAR - Risk management plan

English (EN) (18.92 MB - PDF)

**First published:** 30/11/2023

[View](/en/documents/rmp/inaqovi-epar-risk-management-plan_en.pdf)

## Product information

Inaqovi : EPAR - Product information

English (EN) (444.32 KB - PDF)

**First published:** 30/11/2023

**Last updated:** 10/03/2025

[View](/en/documents/product-information/inaqovi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-723)

български (BG) (479.39 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/bg/documents/product-information/inaqovi-epar-product-information_bg.pdf)

español (ES) (423.25 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/es/documents/product-information/inaqovi-epar-product-information_es.pdf)

čeština (CS) (433.34 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/cs/documents/product-information/inaqovi-epar-product-information_cs.pdf)

dansk (DA) (413.92 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/da/documents/product-information/inaqovi-epar-product-information_da.pdf)

Deutsch (DE) (428.98 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/de/documents/product-information/inaqovi-epar-product-information_de.pdf)

eesti keel (ET) (411.76 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/et/documents/product-information/inaqovi-epar-product-information_et.pdf)

ελληνικά (EL) (493.25 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/el/documents/product-information/inaqovi-epar-product-information_el.pdf)

français (FR) (430.34 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/fr/documents/product-information/inaqovi-epar-product-information_fr.pdf)

hrvatski (HR) (451.32 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/hr/documents/product-information/inaqovi-epar-product-information_hr.pdf)

íslenska (IS) (412.02 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/is/documents/product-information/inaqovi-epar-product-information_is.pdf)

italiano (IT) (427.54 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/it/documents/product-information/inaqovi-epar-product-information_it.pdf)

latviešu valoda (LV) (447.04 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/lv/documents/product-information/inaqovi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (471.73 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/lt/documents/product-information/inaqovi-epar-product-information_lt.pdf)

magyar (HU) (472.12 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/hu/documents/product-information/inaqovi-epar-product-information_hu.pdf)

Malti (MT) (494.45 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/mt/documents/product-information/inaqovi-epar-product-information_mt.pdf)

Nederlands (NL) (415.45 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/nl/documents/product-information/inaqovi-epar-product-information_nl.pdf)

norsk (NO) (409.91 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/no/documents/product-information/inaqovi-epar-product-information_no.pdf)

polski (PL) (481.8 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/pl/documents/product-information/inaqovi-epar-product-information_pl.pdf)

português (PT) (413.18 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/pt/documents/product-information/inaqovi-epar-product-information_pt.pdf)

română (RO) (462.83 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/ro/documents/product-information/inaqovi-epar-product-information_ro.pdf)

slovenčina (SK) (457.7 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/sk/documents/product-information/inaqovi-epar-product-information_sk.pdf)

slovenščina (SL) (469.98 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/sl/documents/product-information/inaqovi-epar-product-information_sl.pdf)

Suomi (FI) (415.14 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/fi/documents/product-information/inaqovi-epar-product-information_fi.pdf)

svenska (SV) (411.52 KB - PDF)

**First published:**

30/11/2023

**Last updated:**

10/03/2025

[View](/sv/documents/product-information/inaqovi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000247810 10/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Inaqovi : EPAR - All authorised presentations

English (EN) (17.3 KB - PDF)

**First published:** 30/11/2023

[View](/en/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-964)

български (BG) (36.31 KB - PDF)

**First published:**

30/11/2023

[View](/bg/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.56 KB - PDF)

**First published:**

30/11/2023

[View](/es/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (24.56 KB - PDF)

**First published:**

30/11/2023

[View](/cs/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.96 KB - PDF)

**First published:**

30/11/2023

[View](/da/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.17 KB - PDF)

**First published:**

30/11/2023

[View](/de/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.09 KB - PDF)

**First published:**

30/11/2023

[View](/et/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (35.38 KB - PDF)

**First published:**

30/11/2023

[View](/el/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_el.pdf)

français (FR) (13.3 KB - PDF)

**First published:**

30/11/2023

[View](/fr/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.21 KB - PDF)

**First published:**

30/11/2023

[View](/hr/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.29 KB - PDF)

**First published:**

30/11/2023

[View](/is/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.31 KB - PDF)

**First published:**

30/11/2023

[View](/it/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (35.37 KB - PDF)

**First published:**

30/11/2023

[View](/lv/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.28 KB - PDF)

**First published:**

30/11/2023

[View](/lt/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (32.3 KB - PDF)

**First published:**

30/11/2023

[View](/hu/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (31.09 KB - PDF)

**First published:**

30/11/2023

[View](/mt/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.8 KB - PDF)

**First published:**

30/11/2023

[View](/nl/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.02 KB - PDF)

**First published:**

30/11/2023

[View](/no/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_no.pdf)

polski (PL) (23.93 KB - PDF)

**First published:**

30/11/2023

[View](/pl/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.45 KB - PDF)

**First published:**

30/11/2023

[View](/pt/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.61 KB - PDF)

**First published:**

30/11/2023

[View](/ro/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.42 KB - PDF)

**First published:**

30/11/2023

[View](/sk/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (33.01 KB - PDF)

**First published:**

30/11/2023

[View](/sl/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (13.57 KB - PDF)

**First published:**

30/11/2023

[View](/fi/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.16 KB - PDF)

**First published:**

30/11/2023

[View](/sv/documents/all-authorised-presentations/inaqovi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Inaqovi Active substance

- cedazuridine
- decitabine

International non-proprietary name (INN) or common name

- cedazuridine
- decitabine

Therapeutic area (MeSH) Leukemia, Myeloid Anatomical therapeutic chemical (ATC) code L01BC58

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/005823

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Otsuka Pharmaceutical Netherlands B.V.

Herikerbergweg 292

Opinion adopted 20/07/2023 Marketing authorisation issued 15/09/2023 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Inaqovi : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (115.34 KB - PDF)

**First published:** 27/01/2025

**Last updated:** 10/03/2025

[View](/en/documents/procedural-steps-after/inaqovi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Inaqovi : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (100.53 KB - PDF)

**First published:** 27/01/2025

[View](/en/documents/procedural-steps-after/inaqovi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Inaqovi : Orphan designation withdrawal assessment report

Reference Number: EMA/OD/0000141337

English (EN) (583.08 KB - PDF)

**First published:** 30/11/2023

[View](/en/documents/orphan-maintenance-report/inaqovi-orphan-designation-withdrawal-assessment-report_en.pdf)

Inaqovi : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/402324/2023

English (EN) (4.7 MB - PDF)

**First published:** 30/11/2023

[View](/en/documents/assessment-report/inaqovi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Inaqovi

Adopted

Reference Number: EMA/324132/2023

English (EN) (132.03 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-inaqovi_en.pdf)

#### News on Inaqovi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2024) 15/11/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

#### More information on Inaqovi

This product is no longer an orphan medicine. It was originally designated an orphan medicine on 10 December 2021. Cedazuridine, decitabine was withdrawn from the Union Register of orphan medicinal products by the European Commission in July 2023 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Inaqovi

- [EMEA-003071-PIP01-21-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-003071-pip01-21-m01)
- [Inaqovi - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/inaqovi)

**This page was last updated on** 10/03/2025

## Share this page

[Back to top](#main-content)